Is the microbiome a viable target for precision medicine?

What is the evidence that the microbiome can be used for precision medicine?

The core idea is that each person's microbiome—the collection of bacteria, viruses, fungi, and other microbes living in and on their body—is as unique as their fingerprint, and that this uniqueness can be used to predict disease risk, diagnose conditions, and tailor treatments. Multiple studies confirm that microbial profiles differ between healthy people and those with specific diseases. For example, in inflammatory bowel disease (IBD), gut microbiome signatures are distinct enough to serve as diagnostic biomarkers [2]. Similarly, in depression, specific compositional and functional changes in the gut microbiome have been identified, and researchers are evaluating whether these can be used as novel diagnostic tools [3]. In pancreatic cancer, oral microbial shifts can be detected years before diagnosis, suggesting a potential early-warning role [5]. These findings come from a range of study types—including large-scale sequencing studies and clinical cohorts—and together they build a consistent picture: the microbiome carries disease-relevant information that could be harnessed for precision medicine.

The evidence extends beyond diagnosis to treatment response. In asthma, for instance, studies show that the microbiome and epigenome interact with common medications like corticosteroids, and that these interactions help explain why some patients respond well while others do not [7]. This means that a patient's microbiome profile could one day guide which drug or dose is most likely to work for them. A 2021 review in Nature Reviews Gastroenterology & Hepatology, which analyzed evidence across six disease groups (including cancer, metabolic disease, and autoimmune conditions), concluded that the microbiome holds promise for stratifying existing treatments and for developing novel therapies [8]. Across the 14 papers reviewed here, the majority support the idea that the microbiome is a viable target—but they also consistently warn that the evidence is still early and that more rigorous, larger studies are needed before it can be used in routine clinical care.

What are the biggest challenges to making microbiome precision medicine a reality?

The main obstacles are complexity, lack of standardization, and insufficient mechanistic understanding. The microbiome is incredibly diverse—both within and between individuals—and it is influenced by diet, environment, genetics, and medications, making it hard to isolate cause from effect [4][9]. For example, while studies show that gut microbiome changes are linked to colon cancer, it is not always clear whether the microbial changes cause the cancer or are a consequence of it [12]. Similarly, in respiratory diseases, the link between the lung microbiome and disease pathogenesis is not yet robust enough to consider the microbiome a reliable drug target [6]. This lack of causal clarity is a major barrier.

Another challenge is that there is no agreed-upon standard for how to collect, process, and analyze microbiome samples. Different labs use different sequencing methods, different bioinformatics pipelines, and different statistical approaches, making it difficult to compare results across studies or to develop a test that works reliably for all patients [8][10]. A 2023 review in Nature Reviews Microbiology notes that these methodological issues, along with the need for longitudinal studies that track both the microbiome and host response over time, are critical hurdles [4]. Finally, ethical and regulatory issues remain—such as how to handle the vast amount of personal data generated and how to ensure that microbiome-based treatments are safe and effective [9][11]. Despite these challenges, the field is moving forward, with advances in machine learning and multi-omics (combining data from genes, proteins, and metabolites) offering new ways to make sense of the complexity [10].

What are the most promising approaches for using the microbiome in precision medicine?

Several concrete strategies are being developed, each with different levels of evidence. One of the most advanced is the use of microbial extracellular vesicles (EVs)—tiny lipid-bound particles released by bacteria that carry proteins, nucleic acids, and other molecules. These EVs can be found in feces, blood, and urine, and their profiles differ between patients with inflammatory diseases, metabolic disorders, and cancers compared to healthy individuals [1]. Because they are stable and can be collected non-invasively, they are being explored as biomarkers for early disease detection and risk assessment [1]. Another promising approach is the use of engineered probiotics and defined microbial consortia—rather than giving a single bacterial strain, researchers are designing communities of microbes that work together to restore a healthy gut ecosystem [2][11]. These 'next-generation' therapeutics are being tested in clinical trials for conditions like IBD and metabolic syndrome.

Fecal microbiota transplantation (FMT) is already used clinically for recurrent C. difficile infection, and researchers are now exploring whether it can be adapted for other diseases, such as colon cancer and metabolic disorders, by selecting donors based on the recipient's specific microbial deficiencies [11][12]. Finally, the integration of microbiome data with other 'omics' data (like genetics and metabolomics) is seen as a key step toward truly personalized treatment. Machine learning algorithms are being applied to these complex datasets to identify microbial signatures that predict disease or drug response [10]. For example, in asthma, combining microbiome and epigenetic data has identified immune pathways (like IL-2 and TNF-α) that could be targeted with new drugs [7]. While none of these approaches are yet standard of care, they represent the most active and evidence-backed avenues for turning microbiome science into precision medicine tools.

About These Sources

This answer is built on 12 peer-reviewed studies — published from 2021 to 2025, 6 from 2024 or later, 7 in Q1 journals, collectively cited 561 times — selected as the most relevant from 14 studies that passed quality screening, drawn from 48 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions